EVOQ Nano, Inc.
EVŌQ Nano is a nanoscience company dedicated to engineering innovative nanoparticles for healthcare, materials, and textile industries. Their mission is to combat antimicrobial resistance (AMR) by developing advanced nanotechnologies, including a patented laser nanofabrication process that produces stable, sub-10 nm nanoparticles. Their flagship product EVQ-218 is a non-ionic silver nanoparticle with demonstrated efficacy against drug-resistant bacteria and fungi, with potential applications in medical devices, therapeutics, and antimicrobial solutions. The company is actively advancing its research, development, and clinical trials, including a significant milestone with FDA approval processes for inhaled therapies targeting pulmonary infections in cystic fibrosis patients. EVŌQ Nano is backed by $20 million in seed funding, with strategic partnerships and a team of experts in nanoscience and biotech.
Industries
Nr. of Employees
small (1-50)
EVOQ Nano, Inc.
Salt Lake City, Utah, United States, North America
Products
Surfactant-free non-ionic metal nanoparticle platform for antimicrobial applications
Uniform, sub-10 nm, surfactant-free metal nanoparticle technology designed for antimicrobial use across therapeutics, medical devices, and surface/textile treatments; characterized in peer-reviewed literature and reported to national-standard-comparable metrics.
Surfactant-free non-ionic metal nanoparticle platform for antimicrobial applications
Uniform, sub-10 nm, surfactant-free metal nanoparticle technology designed for antimicrobial use across therapeutics, medical devices, and surface/textile treatments; characterized in peer-reviewed literature and reported to national-standard-comparable metrics.
Services
IND‑enabling preclinical development for inhaled nanoparticle therapeutics
Design and execution of in vitro and in vivo efficacy and safety studies, IND-enabling activities, and regulatory engagement to support transition to Phase I clinical trials for inhaled nanoparticle formulations.
Nanoparticle integration and validation for medical device manufacturing
Co-development, licensing, and testing partnerships to embed nanoparticles into polymers and validate antimicrobial performance on device components such as catheters and fittings.
Commercial application of EPA‑registered antimicrobial surface and textile treatments
Commercial contracts and licensing for application of EPA-registered antimicrobial chemistries to textiles, workspaces, and consumer products.
IND‑enabling preclinical development for inhaled nanoparticle therapeutics
Design and execution of in vitro and in vivo efficacy and safety studies, IND-enabling activities, and regulatory engagement to support transition to Phase I clinical trials for inhaled nanoparticle formulations.
Nanoparticle integration and validation for medical device manufacturing
Co-development, licensing, and testing partnerships to embed nanoparticles into polymers and validate antimicrobial performance on device components such as catheters and fittings.
Commercial application of EPA‑registered antimicrobial surface and textile treatments
Commercial contracts and licensing for application of EPA-registered antimicrobial chemistries to textiles, workspaces, and consumer products.
Expertise Areas
- Laser-based nanofabrication for scale-up
- Nanoparticle materials engineering and surface-state control
- Inhaled nanotherapeutics for pulmonary infections (preclinical)
- Mechanism-driven antimicrobial development (intracellular metabolic disruption)
Key Technologies
- Laser ablation nanoparticle synthesis
- Production of uniform sub-10 nm nanoparticles
- Surfactant-free non-ionic metal nanoparticle formulations
- Nanoparticle embedding in polymer matrices